About Epigenetic Reprogramming & Gene Therapy
The Epigenetic Reprogramming & Gene Therapy category is part of the Longevity & Human Enhancement market map, tracking 14 companies building in this segment. Senolytics, epigenetic reprogramming, exoskeletons, nootropics, and implantable devices pushing the boundaries of human lifespan and performance. Curated by Hartmann Capital's venture research team.
Companies in Epigenetic Reprogramming & Gene Therapy
- Altos Labs — Series A, $3B
- NewLimit — Series B, $175M
- Retro Biosciences — Series B, $1.2B
- Turn Biotechnologies — Series A, $30M
- Life Biosciences — Series C, $207M
- Shift Bioscience — Seed, $18M
- Rejuvenate Bio — Series A, $15M
- Clock.bio — Seed, $5M
- Calico Life Sciences — Corporate, $2B
- Cambrian Biopharma — Series A, $100M
- Fauna Bio — Seed, $4M
- Loyal — Series B, $85M
- LyGenesis — Series B, $25M
- Junevity — Seed, $10M
Frequently Asked Questions
- What companies are in the Epigenetic Reprogramming & Gene Therapy category?
- The Epigenetic Reprogramming & Gene Therapy category includes 14 companies: Altos Labs, NewLimit, Retro Biosciences, Turn Biotechnologies, Life Biosciences, Shift Bioscience, Rejuvenate Bio, Clock.bio, Calico Life Sciences, Cambrian Biopharma, Fauna Bio, Loyal, LyGenesis, Junevity. This is part of the Longevity & Human Enhancement market map maintained by Hartmann Capital.
- How many Epigenetic Reprogramming & Gene Therapy startups are tracked?
- Hartmann Capital tracks 14 companies in the Epigenetic Reprogramming & Gene Therapy segment of the Longevity & Human Enhancement market map.
- What are the best funded Epigenetic Reprogramming & Gene Therapy companies?
- Top funded companies in Epigenetic Reprogramming & Gene Therapy include Altos Labs ($3000M), Calico Life Sciences ($2000M), Retro Biosciences ($1180M), Life Biosciences ($207M), NewLimit ($175M). Browse the full list in the Longevity & Human Enhancement market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.